Aphria (TSX:APH; OTC:APHQF) gave its investors some bragging rights on Monday (Dec. 4) as the company announced it had signed a supplier agreement deal with Shoppers Drug Mart, a Loblaw (TSX:L) company.
This deal directly links a licensed producer (LP) of cannabis and a major retailer in Canada, in what some experts had predicted could be a preferred avenue for the sale of medical cannabis.
Having said that, it is unclear as to whether it Aphria will be the exclusive supplier for Shopper’s Drug Mart moving forward. Under the agreement, Aphria will supply Shoppers Drug Mart with medical cannabis products branded with their name. The expectation is for the products to be sold online, according to Aphria’s statement.
The Canadian pharmacy declared its intentions to join the cannabis market, back in October 2016, when it applied for a producer license with Health Canada. The pharmacy, however, only plans to sell the products.
On Monday, shares of Aphria closed at $11.62 and saw a 1.93 percent growth in its share price during the one-day trading period. On a year-to-date basis, its stock is up 85.92 percent.

Canadian pharmacy seeking to enter cannabis space

“We have no intention of producing medical marijuana, but we do want the ability to dispense medical marijuana to our patients in conjunction with counselling from a pharmacist,” Shoppers Drug Mart spokeswoman Tammy Smitham told CBC News.
In November, it was also revealed that the pharmacy was seeking to staff a new position meant to lead its cannabis efforts.
The Canadian Press reported the job posting for a medical marijuana brand manager detailed this role would direct the “strategy and marketing to doctors and health-care providers in the cannabis space.”
With legalization looming in July 2018 in Canada, cannabis investors hope to maintain momentum on their picks with announcements on legislation, mergers or new partnerships. The deal also offers legitimacy to the sector since it brings an established industry player accepting the role of cannabis moving forward.

Role of pharmacies in medical cannabis market

It is unclear if the Canadian government will update the law to allow pharmacies to sell medical cannabis products directly to consumers. As the law evolves, the parent company of Shoppers Drug Mart had said it was campaigning for updated standards with pharmacies.
Galen Weston, executive chairman of Loblaw, said during an earnings call in 2016 they were arguing with the federal government about the benefit of pharmacies being allowed to sell medical cannabis, according to the Financial Post.
“We are engaging with the federal government and engaging with the provincial government around dispensing medical marijuana directly from our pharmacies,” Weston said. “We think that the pharmacy business is extremely well-suited for processing controlled substances.”
Canadian Health Minister Ginette Petitpas Taylor has expressed the Canadian government is looking to establish plain packaging as the option for all LPs once they are able to sell their products on retail stores next year. These retail spaces will be for the adoption of recreational cannabis products in 2018.

Similar deals in the industry

Earlier this year Cannabis Wheaton Income (TSXV:CBW) announced a partnership deal with an undisclosed independent pharmacy group for the distribution of medical cannabis products.
“We’re willing to take a bet that pharmacies will be included in the distribution channels for medical cannabis,” Hugo Alves, president of Cannabis Wheaton told INN in September. The group operates 40 independent pharmacies across Canada including remote locations.
In March, CanniMed Therapeutics (TSX:CMED) announced its intentions to aid PharmaChoice with the “education and the distribution, sale and marketing of medical cannabis products.”
“We recognize the incredible value medical cannabis has had on the lives of Canadians who have been prescribed the drug and found success in the therapy,” PharmaChoice West CEO, Grady Brown said in a joint statement. “It’s important that we are well prepared to assist patients in achieving their therapeutic goals within the medical cannabis arena.”
Don’t forget to follow us @INN_LifeScience and @INN_Cannabis for real-time news updates!
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

US Election 2020 and Cannabis

Investing in cannabis? Read what experts have to say about cannabis and the US Election!

Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff

Tactile Systems Technology (NASDAQ:TCMD)
Class Period:
May 7, 2018 – June 8, 2020
Deadline: November 30, 2020
For more info: www.bgandg.com/tcmd

Keep reading... Show less

PharmaTher Inc., a wholly-owned subsidiary of Newscope Capital Corporation (“PharmaTher”) (CSE: PHRM) and a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals, is pleased to provide a corporate update on its psychedelic pharmaceuticals program. Since its inception, the Company has built a unique product pipeline for novel uses of ketamine, psilocybin and undisclosed psychedelics. PharmaTher is positioning itself to partner its psilocybin program and panaceAI™, and focus on advancing its novel ketamine product pipeline in Parkinson’s disease, depression and pain via the U.S. Food and Drug Administration (“FDA”) regulatory pathway.

“We have made tremendous progress over the last several months that saw our product pipeline evolve to focus on the massive opportunity and potential of ketamine, an FDA approved drug with a known safety profile, to treat significant unmet medical needs for Parkinson’s disease, depression and pain,” said Fabio Chianelli, CEO of PharmaTher. “With our focus on ketamine through repurposing, combining it with an FDA approved drug and delivering it with our novel microneedle delivery system, we are now positioned to expedite our clinical development objectives by taking advantage of the FDA’s 505(b)(2) regulatory pathway and commercializing disruptive ketamine treatments for mental health and pain disorders.”

Keep reading... Show less

Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from leaders at: Tilray, Inc. (NASDAQ: TLRY), Icanic Brands (OTC: ICNAF) (CSE: ICAN), Aurora Cannabis (NYSE: ACB)(TSX: ACB), and Canopy Growth Corporation (NASDAQ: CGC) (TSX: WEED).

Cannabis leaders are focusing on innovation in premium branding, global expansion, and tight operational execution in the drive towards profitability. Wall Street Reporter highlights the latest comments from industry thought leaders:

Keep reading... Show less

Chemesis International Inc. (the “Company”) (CSE:CSI)(OTCQB:CADMF)(FRA:CWAA

The Company announces that its (former) subsidiary, Natural Ventures PR, LLC (“NVPR”), has sold all of its cannabis assets, and assigned all related liabilities, licenses and permits, to Puerto Rico Industrial Commercial Holdings Biotech Corp. (“PRICH”) in exchange for immediate net cash proceeds to the Company, in respect of its 80% interest in NVRP, of US$450,000. The Company notes that, in connection with, and as a condition to, this transaction, it will cease to be a shareholder of NVPR.

Keep reading... Show less

Progressive Planet Solutions Inc. (TSXV: PLAN) (“PLAN” or “Progressive Planet”), an emerging leader in reducing the carbon footprint of cement products using natural pozzolans, is pleased to announce it has sold and optioned a combined total of 10 million of its 10.5 million shares of Snow Lake Resources.

The sale and option agreements were made with two arms-length purchasers. The first sale was for 1,700,000 shares at $0.04 per share for a total of $68,000 and includes an option granted by PLAN entitling the same party to purchase an additional 4,966,666 shares at $0.04 per share until May 11, 2021 . The second sale was for 1,250,000 shares at $0.04 per share for a total of $50,000 and includes an option granted by PLAN to such party to purchase an additional 2,083,334 shares until August 14, 2021 . As at the date of this news release, PLAN has received $116,000 and will receive another $284,000 if the remaining shares are purchased under the option agreements.

Keep reading... Show less